Intellia Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 59.58, 111.41, 240.13, 469.24, 1010.5 ], "ebit_estimate": [ -429.21, -403.65, -316.44, -76.31, 1142.27 ], "ebitda_estimate": [ -417.68, -375.35, -306.54, -155.1, 54.13 ], "net_income_estimate": [ -417.18, -399.14, -316.54, -113.14, 167.27 ], "per_share_eps_estimate": [ -3.16, -1.68, -0.14, -0.69, 9.96 ], "eps_nri_estimate": [ -3.19, -2.72, -2, -0.69, 1.4 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 4.84, 4.43, 4.21, null, null ], "pretax_income_estimate": [ -417.33, -407.9, -333.23, -97.72, 1368.77 ], "operating_cash_flow_per_share_estimate": [ -2.8, 2.48, 13.05, 40.82, null ], "roa_estimate": [ -48.2, -2.5, -0.27, 20.45, 29.05 ], "roe_estimate": [ -63.13, 112.58, 26.12, 39.45, 10.2 ], "gross_margin_estimate": [ 100, 92.1, 91.67, 90, 90 ], "operating_cash_flow_estimate": [ -332.16, 293.86, 1546.3, 4836.76, null ], "pettm_estimate": [ 0, 0, 0, 0, 1.43 ], "long_term_growth_rate_mean": 18.93, "long_term_revenue_growth_rate_mean": "55.67", "future_per_share_eps_estimate_growth": 65, "future_eps_nri_estimate_growth": 18.93, "future_revenue_estimate_growth": 55.67, "future_ebit_estimate_growth": 10.03, "future_ebitda_estimate_growth": 10.69, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 8.06, "future_pretax_income_estimate_growth": 6.43, "future_book_value_per_share_estimate_growth": -9.83, "future_roa_estimate_growth": 83.54, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.37, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 13.82, 13.88, 14.76, 11.62, 19.12, 31.04, 41.1, 2.74 ], "ebit_estimate": [ -108.14, -111.9, -112.78, -118.88, -111.38, -97.25, -94.06, null ], "ebitda_estimate": [ -104.37, -109.5, -111.37, -120.7, null, null, null, null ], "net_income_estimate": [ -102.12, -106.39, -107.5, -114.97, -107.7, -96.65, -91.22, null ], "per_share_eps_estimate": [ -0.79, -0.78, -0.78, -0.81, -0.73, -0.65, -0.61, null ], "eps_nri_estimate": [ -0.8, -0.79, -0.79, -0.81, -0.72, -0.65, -0.6, -0.61 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 4.8, 4, 3.13, null, null, null, null, null ], "pretax_income_estimate": [ -102.38, -106.54, -107.16, -114.97, -107.7, -96.65, -91.22, null ], "operating_cash_flow_per_share_estimate": [ -1.29, -1.07, -0.09, null, null, null, null, null ], "roa_estimate": [ -10.9, -12.9, -9.2, null, null, null, null, null ], "roe_estimate": [ -12.7, -15, -10.8, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -152.85, -126.19, -10.66, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 18.93, "long_term_revenue_growth_rate_mean": "55.67", "future_per_share_eps_estimate_growth": 65, "future_eps_nri_estimate_growth": 18.93, "future_revenue_estimate_growth": 55.67, "future_ebit_estimate_growth": 10.03, "future_ebitda_estimate_growth": 10.69, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 8.06, "future_pretax_income_estimate_growth": 6.43, "future_book_value_per_share_estimate_growth": -9.83, "future_roa_estimate_growth": 83.54, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.37, "future_operating_cash_flow_per_share_estimate_growth": null }